Astera Labs vs Credo Technology
ALAB and CRDO side by side, both in electronic components and accessories. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALAB and CRDO compare
Astera Labs is the larger company, worth 1.6 times as much as Credo Technology ($44.9B against $28.4B).
On earnings, Credo Technology is cheaper: it trades at 53.7× trailing earnings, against 128× for Astera Labs.
Credo Technology grew revenue faster over the last twelve months (165% versus 98.5% for Astera Labs).
Credo Technology keeps more of each dollar of sales as profit, with a net margin of 33.8% compared with 30.7% at Astera Labs.
Credo Technology scores higher on the StockData Score (13 against 12 for Astera Labs), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALAB | CRDO |
|---|---|---|
| Size and price | ||
| Market cap | $44.9B | $28.4B |
| Share price | $258.70 | $150.99 |
| Change, 1 year | 49.0% | −12.0% |
| Beta (5Y) | 2.83 | 2.51 |
| Employees | 756 | – |
| StockData Score | ||
| Total score | 12 | 13 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 | 4 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 128× | 53.7× (better) |
| P/S | 37.3× | 17.8× (better) |
| P/B | 26.0× | 10.4× (better) |
| EV/EBITDA | 153× | 50.9× (better) |
| P/FCF | 162× | 64.7× (better) |
| FCF yield | 0.62% | 1.5% (better) |
| Fair value | $58.59 | $85.11 |
| Margin of safety | −342% | −77.4% (better) |
| Growth | ||
| Revenue growth (TTM) | 98.5% | 165% (better) |
| Revenue growth, 5Y average | – | 86.8% |
| Net income growth (TTM) | 269% | 330% (better) |
| EPS growth (TTM) | – | 319% |
| Profitability | ||
| Gross margin | 75.1% (better) | 67.1% |
| Operating margin | 22.8% | 31.7% (better) |
| Net margin | 30.7% | 33.8% (better) |
| FCF margin | 23.0% | 27.6% (better) |
| Return on equity | 25.8% | 30.7% (better) |
| Return on invested capital | 101% (better) | 44.5% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 10.05 (better) | 7.40 |
| Altman Z-score | 133.04 (better) | 61.73 |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 73.6% | 70.4% |
| Held by insiders | 11.4% | 11.0% |
| Insider net buying, 12 months | −$779M | −$363M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 6.0% | 6.7% |
Go deeper
- ALAB stock overview
- ALAB income statement
- ALAB valuation and score
- CRDO stock overview
- CRDO income statement
- CRDO valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.